scholarly journals Effect of Advanced Glycation End Products on Human Thyroglobulin’s Antigenicity as Identified by the Use of Sera from Patients with Hashimoto’s Thyroiditis and Gestational Diabetes Mellitus

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
A. Hatzioannou ◽  
I. Kanistras ◽  
E. Mantzou ◽  
E. Anastasiou ◽  
M. Peppa ◽  
...  
Keyword(s):  
Gestational Diabetes ◽  
Advanced Glycation End Products ◽  
Hashimoto’S Thyroiditis ◽  
Serum Antibody ◽  
Hashimoto's Thyroiditis ◽  
Advanced Glycation ◽  
Antibody Reactivity ◽  
Glycation End Products ◽  
End Products

Advanced glycation end products (AGEs) are formed on proteins after exposure to high concentrations of glucose and modify protein’s immunogenicity. Herein, we investigated whether the modification of thyroglobulin (Tg) by AGEs influences its antigenicity and immunogenicity. Human Tg was incubatedin vitrowith increasing concentrations of D-glucose-6-phosphate in order to produce Tgs with different AGE content (AGE-Tg). Native Tg and AGE-Tgs were used in ELISA to assess the serum antibody reactivity of two patient groups, pregnant women with gestational diabetes (GDM), and patients with Hashimoto’s thyroiditis (HT). We producedin vitroAGE-Tg with low and high AGE content, 13 and 49 AGE units/mg Tg, respectively. All HT patients’ sera presented the same antibody reactivity profile against native Tg and AGE-Tgs, indicating that the modification of Tg by AGEs did not alter its antigenicity. Similarly, the GDM patients’ sera did not discriminate among the two forms of Tg, native or artificially glycated, suggesting that the modification of Tg by AGEs might not alter its immunogenicity. The modification of Tg by AGEs has no obvious effect on neither its antigenicity nor, most likely, its immunogenicity. It seems that other Tg modifications might account for the production of aTgAbs in patients with GDM.

Oxidative Stress and Advanced Glycation End Products in Hashimoto's Thyroiditis

Thyroid ◽  
2016 ◽  
Vol 26 (4) ◽  
pp. 504-511 ◽  
Author(s):  
Rosaria M. Ruggeri ◽  
Teresa M. Vicchio ◽  
Mariateresa Cristani ◽  
Rosaria Certo ◽  
Daniela Caccamo ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Advanced Glycation End Products ◽  
Hashimoto’S Thyroiditis ◽  
Hashimoto's Thyroiditis ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

Serum Levels of Soluble Receptor for Advanced Glycation End Products Are Reduced in Euthyroid Children with Newly Diagnosed Hashimoto’s Thyroiditis: A Pilot Study

2021 ◽  
pp. 1-7
Author(s):  
Tommaso Aversa ◽  
Rosaria Maddalena Ruggeri ◽  
Domenico Corica ◽  
Maria Teresa Cristani ◽  
Giorgia Pepe ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Hashimoto’S Thyroiditis ◽  
Pediatric Patients ◽  
Serum Levels ◽  
Hashimoto's Thyroiditis ◽  
Soluble Receptor ◽  
Newly Diagnosed ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

<b><i>Objective:</i></b> No data are available on advanced glycation end products (AGEs) and their soluble receptor (sRAGE) in pediatric patients with Hashimoto’s thyroiditis (HT). The present study was aimed to simultaneously evaluate serum levels of sRAGE, AGEs, and advanced oxidation protein products (AOPPs) and investigate the relationships between these oxidative stress markers and clinical and biochemical parameters of thyroid function in euthyroid children with HT. <b><i>Design:</i></b> This is a case-control study carried out in a single university hospital center. <b><i>Methods:</i></b> We enrolled 19 newly diagnosed euthyroid HT pediatric patients (3 M, 16 F; median age 12.44 years, range 6.54–15.81 years) and 16 age-, sex-, and BMI-matched healthy controls (5 M, 11 F; median age 12.83 years, range 5.68–15.07 years). None was on levothyroxine treatment. The exclusion criteria were autoimmune, inflammatory, and infection comorbidities. Patients did not differ significantly from controls with regard to lipid or for anthropometric parameters. <b><i>Results:</i></b> sRAGE levels were significantly lower in HT patients (median 414.30 pg/mL, range 307.30–850.30 pg/mL) than in controls (561.30, 273.20–1121.60 pg/mL; <i>p</i> = 0.034). No differences emerged between patients and controls with regard to serum AGEs (124.25 AU/g prot, 71.98–186.72 vs. 133.90, 94.06–200.78 AU/g prot, <i>p</i> = 0.707) and AOPPs (1.13 nmol/mL, 0.62–1.83 vs. 1.17, 0.76–1.42 nmol/mL, <i>p</i> = 0.545). <b><i>Conclusions:</i></b> sRAGE levels were decreased in euthyroid children/adolescents at the onset of HT, suggesting that autoimmunity per se seems to play an important role in such a reduction of sRAGE, irrespective of any functional alteration. Children and adolescents suffering from HT may exhibit increased susceptibility to oxidative damage, even when in euthyroid status.

Sulforaphane inhibits formation of advanced glycation end products in vitro

2014 ◽  
Vol 1 (e1) ◽  
pp. 001-001 ◽  
Author(s):  
Kei Fukami ◽  
Takanori Matsui ◽  
Sho-ichi Yamagishi
Keyword(s):  
Advanced Glycation End Products ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Influence of Dopamine on Fluorescent Advanced Glycation End Products Formation Using Drosophila melanogaster

Biomolecules ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 453
Author(s):  
Ana Filošević Vujnović ◽  
Katarina Jović ◽  
Emanuel Pištan ◽  
Rozi Andretić Waldowski
Keyword(s):  
Drosophila Melanogaster ◽  
Advanced Glycation End Products ◽  
Model Organism ◽  
Covalent Modification ◽  
Advanced Glycation ◽  
Biomarkers Of Aging ◽  
Glycation End Products ◽  
End Products

Non-enzymatic glycation and covalent modification of proteins leads to Advanced Glycation End products (AGEs). AGEs are biomarkers of aging and neurodegenerative disease, and can be induced by impaired neuronal signaling. The objective of this study was to investigate if manipulation of dopamine (DA) in vitro using the model protein, bovine serum albumin (BSA), and in vivo using the model organism Drosophila melanogaster, influences fluorescent AGEs (fAGEs) formation as an indicator of dopamine-induced oxidation events. DA inhibited fAGEs-BSA synthesis in vitro, suggesting an anti-oxidative effect, which was not observed when flies were fed DA. Feeding flies cocaine and methamphetamine led to increased fAGEs formation. Mutants lacking the dopaminergic transporter or the D1-type showed further elevation of fAGEs accumulation, indicating that the long-term perturbation in DA function leads to higher production of fAGEs. To confirm that DA has oxidative properties in vivo, we fed flies antioxidant quercetin (QUE) together with methamphetamine. QUE significantly decreased methamphetamine-induced fAGEs formation suggesting that the perturbation of DA function in vivo leads to increased oxidation. These findings present arguments for the use of fAGEs as a biomarker of DA-associated neurodegenerative changes and for assessment of antioxidant interventions such as QUE treatment.

Sign in / Sign up

Export Citation Format

Share Document